Influenza, Human: all 2,265 studies

Page 8 of 23. Open to participants first (174), then studies with results posted, then the rest; newest registration first within each.

• A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 YearsCompletedNCT00952419Phase 2Results posted
• A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the ElderlyCompletedNCT00952276Phase 2Results posted
• Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in AdultsCompletedNCT00951041Phase 2Results posted
• A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal InfluenzaCompletedNCT00949533Phase 3Results posted
• Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose LevelsCompletedNCT00944073Phase 2Results posted
• Sanofi H1N1 + TIV - Adults and ElderlyCompletedNCT00943878Phase 2Results posted
• Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly PopulationsCompletedNCT00943631Phase 2Results posted
• CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly PopulationsCompletedNCT00943488Phase 2Results posted
• Sanofi Pasteur, TIV + H1N1, Pediatric PopulationCompletedNCT00943202Phase 2Results posted
• A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy ChildrenCompletedNCT00940108Phase 2Results posted
• A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy AdultsCompletedNCT00938639Phase 2Results posted
• Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the ElderlyCompletedNCT00938392Phase 3Results posted
• Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 YearsCompletedNCT00929331Phase 3Results posted
• Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy AdultsCompletedNCT00921947Phase 1/2Results posted
• A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in AdultsCompletedNCT00920374Phase 3Results posted
• A/H5N1/LT Dose Ranging StudyCompletedNCT00908687Phase 2Results posted
• Influenza Vaccine in Pregnant WomenCompletedNCT00905125Phase 2Results posted
• Immune Responses Induced by Different Licensed Influenza VaccinesCompletedNCT00902278Not applicableResults posted
• Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of AgeCompletedNCT00885105Phase 3Results posted
• Influenza Resistance Information StudyCompletedNCT00884117Results posted
• A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)CompletedNCT00877448Phase 1/2Results posted
• A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza VaccineCompletedNCT00873912Phase 4Results posted
• Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy AdultsCompletedNCT00868218Phase 1Results posted
• TCAD vs. Monotherapy for Influenza A in Immunocompromised PatientsCompletedNCT00867139Phase 1/2Results posted
• Clinical Validation of the Point-of-Care MSD Influenza TestTerminatedNCT00863343Results posted
• Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of AgeCompletedNCT00858468Phase 1/2Results posted
• Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult SubjectsCompletedNCT00845429Phase 2Results posted
• Study to Evaluate Impact of School-based Influenza Vaccination on School PopulationsCompletedNCT00844051Not applicableResults posted
• Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly SubjectsCompletedNCT00841763Phase 3Results posted
• Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®CompletedNCT00836953Phase 4Results posted
• A Study to Evaluate the Safety and Immune Responses to Fluzone® VaccinationCompletedNCT00835926Phase 4Results posted
• Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® VaccineCompletedNCT00831987Phase 4Results posted
• Study of Safety and Immunogenicity of Fluzone® in Healthy ChildrenCompletedNCT00831675Phase 4Results posted
• Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 YearsCompletedNCT00825162Phase 4Results posted
• Rapid Flu Tests in Travelers With FeverCompletedNCT00821626Not applicableResults posted
• Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy AdultsCompletedNCT00819013Phase 1Results posted
• Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young AdultsCompletedNCT00814489Phase 1Results posted
• A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.CompletedNCT00812981Phase 3Results posted
• Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical HomeCompletedNCT00812110Phase 4Results posted
• A Multinational Phase III Study of CS-8958 (MARVEL)CompletedNCT00803595Phase 3Results posted
• Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza InfectionCompletedNCT00800605Phase 3Results posted
• Zanamivir Versus Trivalent Split Virus Influenza VaccineCompletedNCT00784784Phase 3Results posted
• Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and OlderCompletedNCT00782431Phase 3Results posted
• Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the ControlCompletedNCT00778895Phase 2Results posted
• Influenza Vaccine Revaccination in Ambulatory Elderly SubjectsCompletedNCT00775450Phase 2Results posted
• Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the ElderlyCompletedNCT00772889Phase 3Results posted
• Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in AdultsCompletedNCT00772109Phase 3Results posted
• Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 YearsCompletedNCT00771615Phase 2Results posted
• Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or OlderCompletedNCT00765076Phase 3Results posted
• Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in ChildrenCompletedNCT00764790Phase 3Results posted
• Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and OlderCompletedNCT00760617Phase 3Results posted
• Randomized Control Trial to Study the Efficacy of the Surgical Mask Versus the N95 Respirator to Prevent InfluenzaCompletedNCT00756574Not applicableResults posted
• Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®CompletedNCT00755274Phase 4Results posted
• Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and OlderCompletedNCT00753272Phase 3Results posted
• Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged > 6 Months of Age.CompletedNCT00750360Phase 4Results posted
• A Study to Evaluate the Safety and Immune Responses to Fluzone® VaccinationCompletedNCT00743275Phase 4Results posted
• Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate VaccineCompletedNCT00742885Phase 2Results posted
• A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus VaccineCompletedNCT00735475Phase 4Results posted
• Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009CompletedNCT00734734Phase 2Results posted
• Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 YearsCompletedNCT00719043Phase 2Results posted
• Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 YearsCompletedNCT00718120Phase 3Results posted
• Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.CompletedNCT00714285Phase 1Results posted
• Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and ReactogenicityCompletedNCT00710866Phase 3Results posted
• A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute InfluenzaCompletedNCT00705406Phase 2Results posted
• H5N1 Priming and Boosting StrategiesCompletedNCT00703053Phase 2Results posted
• A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64CompletedNCT00695669Phase 2Results posted
• Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With FluarixCompletedNCT00693706Phase 1Results posted
• A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza VaccineCompletedNCT00677820Phase 4Results posted
• Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™CompletedNCT00654901Phase 3Results posted
• Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination SchedulesCompletedNCT00652743Phase 3Results posted
• Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and AdolescentsCompletedNCT00645411Phase 2/3Results posted
• Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control VaccinesCompletedNCT00644059Phase 3Results posted
• Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different FormulationsCompletedNCT00633074Phase 2Results posted
• Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult SubjectsCompletedNCT00630331Phase 3Results posted
• Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy AdultsCompletedNCT00623181Phase 2Results posted
• Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and AboveCompletedNCT00620815Phase 2Results posted
• Study to Evaluate the Consistency of Three Consecutive Production Lots of Influenza Vaccine in Healthy Subjects 18 to 49 Years OldCompletedNCT00617851Phase 3Results posted
• Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 YearsCompletedNCT00616928Phase 3Results posted
• Intramuscular Peramivir in Subjects With Uncomplicated Acute InfluenzaTerminatedNCT00610935Phase 3Results posted
• A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged BulkCompletedNCT00586469Phase 4Results posted
• Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a SubgroupCompletedNCT00579345Phase 3Results posted
• Feasibility of Cocooning Immunization Strategy With Influenza VaccineCompletedNCT00570037Not applicableResults posted
• Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)CompletedNCT00566345Phase 3Results posted
• A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy AdultsCompletedNCT00562484Phase 4Results posted
• Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® VaccineCompletedNCT00561002Phase 4Results posted
• Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical ConditionsCompletedNCT00560066Phase 4Results posted
• Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing InfluenzaCompletedNCT00555893Not applicableResults posted
• Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly SubjectsCompletedNCT00551031Phase 2Results posted
• A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.CompletedNCT00545532Phase 3Results posted
• Revaccination With Influenza Vaccine GSK1247446ACompletedNCT00545025Phase 2Results posted
• Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389ACompletedNCT00540592Phase 2Results posted
• Study to Evaluate an Influenza Vaccine CandidateCompletedNCT00540228Phase 2Results posted
• Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlokCompletedNCT00539981Phase 3Results posted
• Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIVCompletedNCT00539864Phase 3Results posted
• Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4CompletedNCT00538512Phase 4Results posted
• Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly AdultsCompletedNCT00538473Phase 2Results posted
• Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly AdultsCompletedNCT00538213Phase 2Results posted
• Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and OverCompletedNCT00532298Phase 2Results posted
• Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly AdultsCompletedNCT00529516Phase 3Results posted
• Trial to Describe the Safety and Immunogenicity of Fluzone®CompletedNCT00524940Phase 2Results posted

← Influenza, Human overview